文献速递免疫规划传染病防控与疫情报告

挪威老年人第二剂COVID-19加强针对重症结局的有效性与持久性:比较单价与二价加强剂的人群队列研究

Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing mono- and bivalent booster doses.
PubMed 文献 · Int J Epidemiol · 2023-01-01

挪威人群队列研究纳入408073名≥75岁已接种至少三剂者,比较第四剂单价或二价mRNA疫苗与第三剂(>24周前)对重症COVID-19结局的保护。接种后2-9周二价BA.1疫苗aHR 0.08(95%CI 0.02-0.32),BA.4-5疫苗aHR 0.27(95%CI 0.14-0.56),单价疫苗aHR 0.34(95%CI 0.26-0.45);单价疫苗保护在33周后无额外保护。

要点

  • 第四剂单价或二价mRNA疫苗较第三剂(>24周前)对≥75岁人群COVID-19相关死亡显示增强保护。
  • 接种后2-9周,二价BA.1疫苗aHR 0.08,BA.4-5疫苗aHR 0.27,单价疫苗aHR 0.34。
  • 单价疫苗在33周后较第三剂无额外保护,保护效应随时间减弱。

核心结论

  • 第四剂较第三剂对重症结局显示增强保护效应,且保护效应随末次接种时间延长而减弱。

研究设计与样本

  • 挪威人群队列研究,覆盖2022年7月1日至2023年1月15日,纳入≥75岁且已接种至少三剂者408073人。
  • 采用Cox比例风险模型估计单价与二价疫苗的疫苗有效性,比较第四剂与第三剂(>24周前)接种者,疫苗状态作为时变协变量并调整潜在混杂因素。

主要发现

  • 接种后2-9周,二价BA.1疫苗aHR 0.08(95%CI 0.02-0.32),二价BA.4-5疫苗aHR 0.27(95%CI 0.14-0.56),单价疫苗aHR 0.34(95%CI 0.26-0.45),均与第三剂>24周前比较。
  • 单价疫苗在33周后较第三剂无额外保护。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on the durability of the protection of a fourth dose of a monovalent or bivalent messenger ribonucleic acid (mRNA) vaccine against coronavirus disease 2019 (COVID-19) among older people during the predominant Omicron period is needed. METHODS: We performed a population-based cohort study in Norway covering the time from 1 July 2022 to 15 January 2023, including individuals ≥75 years of age who had received at least a third dose. Using Cox proportional hazard models on severe COVID-19-associated outcome measures and all-cause mortality, we estimated the vaccine effectiveness of mono- and bivalent vaccines, comparing fourth- to third-dose recipients (>24 weeks ago). Vaccine status was included as a time-varying covariate and models were adjusted for potential confounders. RESULTS: We included 408 073 individuals. A fourth dose with either monovalent or bivalent mRNA vaccine showed increased protection against COVID-19-associated mortality relative to a third dose in individuals ≥75 years of age. We estimated a protective effect for the bivalent BA.1 vaccine [adjusted hazard ratio (aHR) 0.08, 95% CI 0.02-0.32] relative to the bivalent BA.4-5 (aHR 0.27, 95% CI 0.14-0.56) and a monovalent dose (aHR 0.34, 95% CI 0.26-0.45) 2-9 weeks after vaccination compared with recipients with a third dose >24 weeks ago. The increased protective effect waned with no added protection for the monovalent vaccine after 33 weeks compared with a third dose. CONCLUSIONS: Our results indicate an increased protective effect of a fourth dose against severe outcomes compared with a third dose, with decreasing effect with time since the last dose.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Stecher M, Kristoffersen AB, Lie K, et al. Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing mono- and bivalent booster doses. Int J Epidemiol. 2023. PMID: 37608733. doi:10.1093/ije/dyad114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。